肺癌是全球高死亡率的肿瘤之一，该肿瘤侵袭转移能力强，治疗难度大，预后效果差，严重影响患者身心健康。血管生成是肺癌生长转移的主要途径之一，血管生成相关因子的分泌刺激内皮细胞参与血管生成的出芽、延伸以及管腔成熟的各个阶段。中药被广泛应用于肺癌的现代药理研究中，抑制肿瘤微环境中血管生成因子的表达，阻断关键通路，延缓肺癌进展中异常血管网络生成。综述多种中药通过调节内皮细胞中缺氧诱导因子-1α（HIF-1α）、血管内皮生长因子（VEGF）、成纤维细胞生长因子（bFGF）、血小板源性生长因子（PDGF）、基质金属蛋白酶（MMPs）、血管生成素（Ang）以及细胞因子的表达，调控血管生成过程相关信号通路VEGFA/VEGFR2、PI3K/AKT、MEK/ERK、JAK2/STAT3和DLL4/Notch1，具有抑制血管内皮增殖迁移成管的药理作用和作用机制，从而为抗肺癌血管生成药物的研发提供新的方法和思路。

Lung cancer is among the cancers with the highest fatality rates globally. The tumor exhibits significant invasive and metastatic capabilities, poses treatment challenges, and has a grim prognosis, severely impacting patients' physical and mental well-being. Angiogenesis is a primary mechanism for the proliferation and spread of lung cancer. The release of angiogenesis-related factors activates endothelial cells to engage in the processes of sprouting, elongation, and lumen maturation during angiogenesis. Traditional Chinese medicine is extensively utilized in contemporary pharmacological research on lung cancer, suppressing the production of angiogenic factors within the tumor microenvironment, obstructing critical pathways, and postponing the development of aberrant vascular networks throughout the course of lung cancer. This article examines the impact of various traditional Chinese medicines on the expression of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), matrix metalloproteinases (MMPs), angiopoietin (Ang), and cytokines in endothelial cells, while also regulating the angiogenesis-related signaling pathways VEGFA/VEGFR2, PI3K/Akt, MEK/ERK, JAK2/STAT3, and DLL4/Notch1. It possesses the pharmacological action and mechanism of obstructing the proliferation and migration of vascular endothelial cells into tubular structures, thereby offering a novel approach and mechanism for the advancement of anti-lung cancer angiogenesis therapeutics.

R979.1

国家自然科学基金资助项目（82074088）； 山东省中医药科技项目（M-2022146）